^
Association details:
| Biomarker: | PALB2 deletion |
|---|---|
| Cancer: | Uterine Corpus Leiomyosarcoma |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Correlative results from NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.
Published date:
05/26/2022
Excerpt:
NCI protocol #10250 is a single-arm, multicenter, phase 2 trial evaluating O+T in advanced uLMS pts with progression on ≥1 prior line....31% (5/16) pts had a mutation (Mut) or homozygous deletion (Hd) in the HR panel: ATRX Mut (2), ATR Mut, PALB2 Hd, RAD51B Hd. Pts with PALB2 and RAD51B Hd had longest PFS on study.
Secondary therapy:
temozolomide
DOI:
10.1200/JCO.2022.40.16_suppl.11509
